MLNM drops compounds for prostate cancer, RA

Millennium (MLNM) discontinued development of MLN2704 for prostate cancer and MLN1202 for rheumatoid arthritis (RA). MLNM said MLN2704 does not have a sufficient therapeutic window based on a Phase I/II trial. The product is an anti- PSMA antibody conjugated to the DM1 toxin that uses maytansinoid tumor-activated prodrug (TAP) technology from Immunogen (IMGN). MLNM may still develop the antibody conjugated to other toxins. ...